Biomaterials and Delivery Systems for Regenerative Medicine

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 403

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Biology and Human Genetics, Faculty of Medicine, University of Niš, 18000 Niš, Serbia
2. Department for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, 18000 Niš, Serbia
Interests: stem cells; tissue engineering; regenerative medicine; adipose tissue; macrophages; in vitro cell models; in vivo animal models; wound healing; chronic wounds; biomaterials; molecular and human genetics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Department of Biology and Human Genetics, Faculty of Medicine, University of Niš, 18000 Niš, Serbia
2. Department for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, 18000 Niš, Serbia
Interests: regeneration of skeletal tissues assisted by biomaterials and stem cells; tissue engineering models; macrophages; examination of biological activity of the various substances in animal models in vivo and cell models in vitro
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce the new Special Issue for Pharmaceutics entitled "Biomaterials and Delivery Systems for Regenerative Medicine".

Various biomaterials are constantly used in tissue engineering and regenerative medicine, and there is still a great need for improvement in this area. Biomaterials used in regenerative medicine should be biocompatible and should enable cell adhesion, migration, proliferation, differentiation, and regeneration. Biomaterials should mimic the natural structure of the extracellular matrix and represent a physiological microenvironment for cellular functions. They should induce tissue regeneration and have adequate biodegradability properties, as well as the ability to deliver bioactive substances if they are used as carriers and delivery systems. Prior to potential clinical applications, biomaterials have to be thoroughly tested in preclinical studies using various in vitro cell models and in vivo animal models.

This Special Issue on "Biomaterials and Delivery Systems for Regenerative Medicine" encourages authors to submit their original research or review articles that bring newly developed biomaterials, methods, solutions, delivery systems, tissue engineering solutions, and models for regenerative medicine and pharmaceutical purposes. Topics include, but are not limited to, the following: biomaterial design and testing, smart biomaterials, biocompatibility testing in vitro, biocompatibility testing in vivo, regenerative potential testing, stem cells, 2D and 3D cell cultures, in vitro cell models for soft and hard tissue regeneration, in vitro cell models for testing drugs and medical devices for regenerative medicine applications, personalized in vitro cell models, matrices and scaffolds for 3D cell models, biomaterials as delivery systems, 3D printing, bioreactors, wound healing, and pharmaceutics in regenerative medicine. Additionally, the application of machine learning methods in biomaterial design and testing is welcomed.

Dr. Sanja Stojanović
Prof. Dr. Stevo Najman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomaterials
  • scaffolds
  • soft and hard tissue regeneration
  • in vitro cell models
  • in vivo animal models
  • biocompatibility in vitro
  • biocompatibility in vivo
  • 3D printing
  • stem cells
  • bioreactors
  • organ-on-chip
  • delivery systems
  • wound healing
  • machine learning in regenerative medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 4066 KiB  
Article
Intravenous Administration of sRNA Nanoparticles for Treatment of Osteoporosis in Mice
by Xuemeng Mu, Xinyi Du, Huitian Han, Fei Liu, Zhifa Zheng, Jing Hao, Lijin Liu, Su Liu, Ze Wei, Changfa Huang, Annan Liang, Wei Zou, Lina Zhao, Zhihong Wu and Jia Zhang
Pharmaceutics 2025, 17(6), 789; https://doi.org/10.3390/pharmaceutics17060789 - 17 Jun 2025
Viewed by 130
Abstract
Background: With the intensification of population aging, osteoporosis has become one of the significant public health issues affecting human health. Currently available medications for treating osteoporosis are associated with various adverse effects and resistance issues. Oligonucleotide drugs show great potential. Effective delivery [...] Read more.
Background: With the intensification of population aging, osteoporosis has become one of the significant public health issues affecting human health. Currently available medications for treating osteoporosis are associated with various adverse effects and resistance issues. Oligonucleotide drugs show great potential. Effective delivery systems are essential to enhance the stability, bioavailability, and targeting of sRNA drugs. Lipid nanoparticles (LNPs) show promise as alternative osteoporosis therapeutics. This study explores the potential of LNPs as an effective delivery system to treat osteoporosis. Methods: LNPs were prepared using microfluidic techniques with varying lipid compositions, and characterized in terms of size, zeta potential, and entrapment efficiency (EE%). Dynamic light scattering (DLS) was employed to determine the size of the LNPs. The zeta potential was measured using electrophoretic light scattering. The pharmacodynamic effects and safety were then evaluated in a mouse model through intravenous administration. Results: Several lipid nanoparticle (LNP) formulations with different nitrogen/phosphorus ratios and different DMG-PEG2000 ratios were examined, and a lead candidate that supports delivery of sRNA in animal models of osteoporosis was identified. In OVX mice, LNP-sRNA significantly improved bone mineral density (BMD), trabecular microstructure, and biomechanical strength. Safety assessments revealed no systemic toxicity. It is shown that the optimized LNPs can serve as a promising delivery system to mediate sRNA delivery to bone tissue. Conclusions: After comparison of in vitro and in vivo properties, the optimized LNPs demonstrated good comprehensive performance as a delivery system for osteoporosis treatment. These results highlight the potential of the optimized LNPs as an ideal delivery system for osteoporosis, offering improved therapeutic efficacy and reduced systemic side effects. Full article
(This article belongs to the Special Issue Biomaterials and Delivery Systems for Regenerative Medicine)
Show Figures

Graphical abstract

Back to TopTop